Recently, reports have shown EZH2 frequently overexpressed in several human epithelial cancers, including prostate cancer [10], breast cancer [11], gastric cancer [11], non-small-cell lung cancer [12], esophageal cancer [13], melanomas [9], oral cancer [14], and endometrial carcinomas [15]; it is additionally associated with increased tumor cell proliferation and exacerbated outcomes [16]. The gene discussed is EZH2; the disease is prostate carcinoma.